-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China News Service, AugustAccording to Hong Kong's "Ta Kung Pao" report, in the past 10 years, the global incidence of intrahepatic cholangiocarcinoma has continued to increa.
The clinical study was designed and initiated by the Department of Oncology, Faculty of Medicine, The Chinese University of Hong Kong, in collaboration with the Department of Imaging and Interventional Radiolo.
Professor Yu Junhao, Professor of the Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, explained the efficacy of local therapy in treating intrahepatic cholangiocarcinoma: "SIRT is the treatment of liver tumors by injecting radioactive substances containing 'yttrium 90' through arteri.
The study results showed that patients who received SIRT alone had a median overall survival of 16 months; patients who received a combination of SIRT and standard chemotherapy had a median overall survival of 26 mont.
Lead researcher Pr.